Patient Need

Immunotherapy has emerged as an effective treatment for some cancer indications over the last decade, but considerable limitations, challenges and opportunities remain.

For example, T cell based cancer treatments have offered some patients with some indications, remarkable therapeutic benefits -- but little improvement, for many. 

NK cells and cytokines are part of the body's natural immune system and can destroy disease cells in a broad range of indications

Natural Killer (NK) cells and cytokines are part of the body’s natural immune system, and can destroy disease cells across a very broad range of indications – from oncology and neuromuscular disease, to autoimmune and virology indications. 
 

Dragonfly’s drugs are designed to have a distinct safety profile, offering a broad therapeutic window where patient benefits can be considerable, and the challenges of disease treatment are limited. 

Dragonfly's cytokines invigorate effector cells and fuel their activity

Dragonfly's TriNKETs and Cytokines can both provide patient benefit as a monotherapy, and dramatically enhance the benefits of traditional therapeutic agents.

Dragonfly’s TriNKETs amplify the power of traditional immunotherapy by engaging both the adaptive and innate immune systems, directly and indirectly, with a single mechanism. 

Our TriNKETs potently stimulate both Natural Killer cells in the innate immune system, and CD8 T cells in the adaptive immune system, offering a distinctly powerful therapeutic agent with a refreshing safety profile, in a single drug. 
 

Both Dragonfly’s TriNKETs and CYTOKINEs are designed to work combinatorily with a wide range of other I/O drugs, as well as with other traditional treatment approaches such as, in oncology, chemotherapy and radiation.
 

Dragonfly’s TriNKETs and CYTOKINEs have extraordinary CMC profiles that allow them to titre well, purify simply, concentrate easily and be stable under a wide range of conditions.